About
BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licens
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 8,972 investors are based in London, England, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech
- Location
- London, UK
Contact Information
Find more investors like BTG
Search Investors